Ajanta Pharma Ltd has announced the schedule for its upcoming analyst and institutional investor meetings set for August 2026. The company will engage with market participants through one-on-one sessions at the Nuvama India Conference in Singapore and Hong Kong from August 11 to 13, 2026, and attend the Motilal Annual Global Conference in Mumbai on August 18, 2026. These engagements provide investors with direct access to management insights, though discussions are restricted to already published information.

The disclosure was made pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company confirmed that all interactions during these scheduled events will be strictly based on publicly available data, ensuring compliance with regulatory norms regarding selective disclosure.

Meeting Schedule

The detailed itinerary for the analyst and institutional investor engagements is outlined below:

Gaurang Chinubhai Shah, Senior Vice President – Legal & Company Secretary, signed the intimation on August 5, 2026. The company noted that the schedule is subject to change due to exigencies on either side. Investors are advised to monitor official communications for any updates regarding timing or venue adjustments.

Ajanta Pharma has published the written transcript of its earnings call for the first quarter of FY27 (Q1FY27), providing investors with a detailed textual record of management’s discussion on the quarter ended June 30, 2026. The conference call was originally held on July 30, 2026, at 4:15 p.m., and the transcript complements the audio recording previously released by the company. This disclosure ensures that all stakeholders have access to the specific questions raised by analysts and the precise responses provided by executive leadership regarding financial performance and strategic outlook.

The filing was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, which mandates listed entities to provide access to earnings call materials to ensure transparency and equal information dissemination. The transcript is hosted directly on the company’s investor relations portal and was simultaneously dispatched to both the BSE Limited and the National Stock Exchange of India on August 3, 2026.

Accessing the Transcript

Investors can review the complete text of the proceedings through the official link provided in the exchange filing. The document covers the entire duration of the call, including management presentations and the question-and-answer session.

Regulatory Compliance and Sign-off

The disclosure was signed by Gaurang Chinubhai Shah, Senior Vice President – Legal & Company Secretary at Ajanta Pharma. The digital signature confirms the authenticity of the document, dated August 3, 2026, at 16:09:57 +05'30'. This step completes the regulatory requirement for post-call documentation, following the initial release of the audio recording.

Analytical Context

While the transcript itself contains the raw data of management’s commentary, its publication allows for a more granular analysis of the company’s guidance and operational updates compared to audio-only reviews. Investors can now cross-reference specific statements on revenue drivers, margin pressures, or pipeline developments with the financial figures reported in the quarterly results. The availability of both audio and text formats underscores Ajanta Pharma’s commitment to regulatory compliance and investor accessibility.